JP2013530237A5 - - Google Patents

Download PDF

Info

Publication number
JP2013530237A5
JP2013530237A5 JP2013518685A JP2013518685A JP2013530237A5 JP 2013530237 A5 JP2013530237 A5 JP 2013530237A5 JP 2013518685 A JP2013518685 A JP 2013518685A JP 2013518685 A JP2013518685 A JP 2013518685A JP 2013530237 A5 JP2013530237 A5 JP 2013530237A5
Authority
JP
Japan
Prior art keywords
group
salt
compound
following groups
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530237A (ja
JP5799479B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042507 external-priority patent/WO2012006202A1/en
Publication of JP2013530237A publication Critical patent/JP2013530237A/ja
Publication of JP2013530237A5 publication Critical patent/JP2013530237A5/ja
Application granted granted Critical
Publication of JP5799479B2 publication Critical patent/JP5799479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518685A 2010-07-07 2011-06-30 Rhoキナーゼインヒビター Active JP5799479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36203610P 2010-07-07 2010-07-07
US61/362,036 2010-07-07
PCT/US2011/042507 WO2012006202A1 (en) 2010-07-07 2011-06-30 Rho kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013530237A JP2013530237A (ja) 2013-07-25
JP2013530237A5 true JP2013530237A5 (cg-RX-API-DMAC7.html) 2014-08-14
JP5799479B2 JP5799479B2 (ja) 2015-10-28

Family

ID=44514975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518685A Active JP5799479B2 (ja) 2010-07-07 2011-06-30 Rhoキナーゼインヒビター

Country Status (4)

Country Link
US (1) US9079880B2 (cg-RX-API-DMAC7.html)
EP (1) EP2590942B1 (cg-RX-API-DMAC7.html)
JP (1) JP5799479B2 (cg-RX-API-DMAC7.html)
WO (1) WO2012006202A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
PT2903618T (pt) 2012-10-05 2022-08-19 Kadmon Corp Llc Inibidores de rho cinase
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物
JP6423372B2 (ja) 2013-02-28 2018-11-14 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体
CN107108581B (zh) 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
TW201706265A (zh) 2015-03-09 2017-02-16 必治妥美雅史谷比公司 做為Rho激酶(ROCK)抑制劑之內醯胺
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
US10738007B2 (en) 2016-10-24 2020-08-11 Translation Drug Development, LLC Amide compounds as kinase inhibitors, compositions and methods of treatment
CN110099906B (zh) * 2016-10-24 2022-07-26 转化药物开发有限责任公司 作为激酶抑制剂的酰胺化合物
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
JP7210540B2 (ja) * 2017-08-04 2023-01-23 武田薬品工業株式会社 血漿カリクレインの阻害剤およびその使用
DK3684767T3 (da) 2017-09-22 2024-07-15 Jubilant Epipad LLC Heterocykliske forbindelser som pad-inhibitorer
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
CN107903185B (zh) * 2017-11-08 2020-05-26 四川大学 新型eEF2K抑制剂的制备及应用
SMT202400203T1 (it) 2017-11-24 2024-07-09 Jubilant Episcribe Llc Composti eterociclici come inibitori di prmt5
CA3093527A1 (en) 2018-03-13 2019-09-19 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
JP7490569B2 (ja) * 2018-04-24 2024-05-27 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物、組成物および処置方法
EP3843845A4 (en) 2018-08-29 2022-05-11 University Of Massachusetts INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516384B2 (ja) * 1987-11-27 1996-07-24 保土谷化学工業株式会社 ペンズアミド誘導体
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
JPH11130751A (ja) 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
EP1339668A2 (en) 2000-11-28 2003-09-03 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE10250743A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
FR2862965B1 (fr) 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
EP1807390A4 (en) 2004-11-04 2008-07-02 Neurogen Corp ARYL ALKYL UREA AS CB1 ANTAGONISTS
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
EP2068878B1 (en) 2006-09-20 2019-04-10 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
ES2627221T3 (es) 2006-12-28 2017-07-27 Rigel Pharmaceuticals, Inc. Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008157330A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
WO2009027392A1 (en) 2007-08-27 2009-03-05 Abbott Gmbh & Co. Kg 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
EP2194045A4 (en) 2007-08-30 2011-09-21 Takeda Pharmaceutical Substituted pyrazole derivative
EP2231600B1 (en) 2007-11-16 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
AR071069A1 (es) 2008-03-26 2010-05-26 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2013530237A5 (cg-RX-API-DMAC7.html)
JP2013531013A5 (cg-RX-API-DMAC7.html)
JP2013544797A5 (cg-RX-API-DMAC7.html)
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
JP2019520396A5 (cg-RX-API-DMAC7.html)
JP2014533259A5 (cg-RX-API-DMAC7.html)
JP2019518766A5 (cg-RX-API-DMAC7.html)
JP2019517475A5 (cg-RX-API-DMAC7.html)
JP2016510032A5 (cg-RX-API-DMAC7.html)
JP2016510033A5 (cg-RX-API-DMAC7.html)
ES2732902T3 (es) Bencimidazol-2-aminas como inhibidores de MIDH1
JP2019520402A5 (cg-RX-API-DMAC7.html)
JP2018501285A5 (cg-RX-API-DMAC7.html)
JP2009502830A5 (cg-RX-API-DMAC7.html)
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
WO2012107706A8 (en) Phenothiazine diaminium salts and their use
JP2018507877A5 (cg-RX-API-DMAC7.html)
JP2014521653A5 (cg-RX-API-DMAC7.html)
JP2010529134A5 (cg-RX-API-DMAC7.html)
JP2014514360A5 (cg-RX-API-DMAC7.html)
JP2016505042A5 (cg-RX-API-DMAC7.html)
JP2015510942A5 (cg-RX-API-DMAC7.html)
JP2018527295A5 (cg-RX-API-DMAC7.html)
JP2009539848A5 (cg-RX-API-DMAC7.html)
KR102493943B1 (ko) 포유류 티로신 키나제 ROR1 활성의 저해제로서 유용한 2-페닐-3H-이미다조[4,5-b]피리딘 유도체